Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

JA14-Tools
Association News Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Association News To cite this article: (1991) Association News, Oncology Issues, 6:1, 7-8, DOI: …
SO04-President
Ballentine (Fellowship Seek-and-Find Exercise)
tools Approved Drugs • The U.S. Food and Drug Administration (FDA) granted accelerated approval to Bavencio® (avelumab) (EMD Serono, Inc., emdserono.com) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma. Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. This is the first FDA-approved product to treat …
MA15-Tools
JA07-Action
MJ03-President
New Molecular Entities • ZynyzTM (retifanlimab-dlwr) – Incyte became the latest company to bring a PD-1 inhibitor to market with FDA’s accelerated approval this month for use of its novel agent as treatment for metastatic or recurrent Merkel cell carcinoma. Support for the approval comes from a single arm study that examined both response to therapy and duration of response in 65 patients …
Comprehensive biomarker testing can play an important role in the personalized treatment for patients with non-small cell lung cancer (NSCLC). In honor of Lung Cancer Awareness Month 2021, the Association of Community Cancer Centers (ACCC) and Amgen co-hosted a live discussion with a panel of multidisciplinary oncology experts, focusing on the hurdles cancer care teams face when implementing biomarker …
Molecular-Testing-Learning-Labs-Process
During 2014, ACCC conducted experiential Learning Labs focused on improving molecular testing at eight member cancer programs. The process followed is described below. Collecting Baseline Data Participating centers gathered baseline performance data on molecular testing in lung cancer at the start of the project, to assess their current clinical practices and workflows. The process of collecting this …
PowerPoint Presentation Case 1: Surgeon’s Two Cents ANDREW COWAN, MD, PHD NMSCO ANNUAL CONFERENCE, 9/15/23 Tonsil?  2.8 x 2.6 cm mass in the left pharyngeal space [assume oropharynx]  The oropharynx is bounded anteriorly by the oral cavity, superiorly by the nasopharynx, and inferiorly by the larynx and the hypopharynx. Nasopharynx  Bounded anteriorly by …
New Molecular Entities • ZynyzTM (retifanlimab-dlwr) – Incyte became the latest company to bring a PD-1 inhibitor to market with FDA’s accelerated approval this month for use of its novel agent as treatment for metastatic or recurrent Merkel cell carcinoma. Support for the approval comes from a single arm study that examined both response to therapy and duration of response in 65 patients …
New Molecular Entities • ZynyzTM (retifanlimab-dlwr) – Incyte became the latest company to bring a PD-1 inhibitor to market with FDA’s accelerated approval this month for use of its novel agent as treatment for metastatic or recurrent Merkel cell carcinoma. Support for the approval comes from a single arm study that examined both response to therapy and duration of response in 65 patients …
Health Care Workforce Shortage Across the Nation For years, the US health care workforce has struggled to keep pace with burnout, retirement, or finding people needed to do the work. By the numbers: • By 2025, there could be a deficit of 200,000 to 450,000 registered nurses in the US available for direct patient care • By 2027, the US faces a shortage of over 3.2 million health care workers …
ND12-Issues
24 accc-cancer.org | January–February 2020 | OI tools Approved Drugs • On Nov. 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Brukinsa™ (zanubrutinib) (BeiGene, beigene.com) for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. • On Nov. 21, the FDA approved Calquence® (acalabrutinib) …
JA07-Legal-Corner